Increasing Patient Safety: Risk Assessment For Small Volume Fluid Management

Autologous cell and gene therapies operate at a scale that exposes critical gaps in conventional aseptic filling approaches, gaps that carry real consequences for patient safety, product integrity, and regulatory compliance.

Manual filling processes struggle to maintain the consistency and accuracy that small-volume aliquotation demands. At this scale, comparable to clinical Phase 1 or even pre-clinical trials, variability becomes a patient safety issue. Add the complexity of cold chain logistics, sterile packaging requirements, and cGMP mandates, and it becomes clear why fluid management remains one of the most underaddressed challenges in cell and gene therapy manufacturing.

This article examines the specific risk factors driving these challenges and makes the case for closed, pump-driven, single-use systems that can deliver the accuracy and sterility assurance autologous therapies require. You will also find practical guidance on developing best practices for automated filling as this category of therapy moves from early-stage to commercial scale.

If your organization is navigating the shift from manual to automated filling, or looking to strengthen your risk assessment framework for small-volume fluid management, this article gives you a foundation to build on. Access the full article to learn more.